From discovery to treatment

Coretag Broad Radioligandtherapy (RLT) Pipeline, addressing hard to treat solid tumors.

Coretag’s most advanced clinical candidates, CyanTag® and CyanCore®, have physical half-lives of approximately 1 hour and 9 hours, respectively. Each compound is composed of a cyanine conjugated to a chelator (like DOTA or DOTAGA). The therapeutic radioisotope prioritized to be used for our First in Human study, is a Beta-therapy, Lutetium-177. However, our pipeline also contains compound labeled with other therapeutic radioisotopes with a later start of clinical trials, including also Lead-212 which is an Alpha-therapy. Lutetium-177 has a half-life of 6.7 days and emits β-particles with a most abundant energy of 0.5 MeV and an average energy of 0.1 MeV. The ranges of these β-particles in tissue are 1.8 mm and 0.5 mm, respectively. Additionally, Lutetium-177 emits photons at 113 and 208 keV, allowing for imaging, biodistribution studies, and absorbed-dose calculations.